121 related articles for article (PubMed ID: 3512075)
41. Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.
Moroz C; Kupfer B; Lindner A; Many M
Cancer Immunol Immunother; 1985; 20(3):236-40. PubMed ID: 2415237
[TBL] [Abstract][Full Text] [Related]
42. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
43. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
44. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
[TBL] [Abstract][Full Text] [Related]
45. Enhancement of natural killer cell activity and interferon production by manganese in young mice.
Smialowicz RJ; Riddle MM; Rogers RR; Luebke RW; Burleson GR
Immunopharmacol Immunotoxicol; 1988; 10(1):93-107. PubMed ID: 2452180
[TBL] [Abstract][Full Text] [Related]
46. Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity.
Parhar RS; Lala PK
Cell Immunol; 1985 Jul; 93(2):265-79. PubMed ID: 3159480
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
48. Induction of LAK-like cells in the peritoneal cavity of mice by inactivated Candida albicans.
Scaringi L; Cornacchione P; Rosati E; Boccanera M; Cassone A; Bistoni F; Marconi P
Cell Immunol; 1990 Sep; 129(2):271-87. PubMed ID: 2166624
[TBL] [Abstract][Full Text] [Related]
49. Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice.
Tzai TS; Shiau AL; Wu CL; Tsai YS
Proc Natl Sci Counc Repub China B; 2000 Apr; 24(2):56-62. PubMed ID: 10809081
[TBL] [Abstract][Full Text] [Related]
50. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
[TBL] [Abstract][Full Text] [Related]
52. Immunomodulation and antitumor effects of MVE-2 in mice.
Talmadge JE; Maluish AE; Collins M; Schneider M; Herberman RB; Oldham RK; Wiltrout RH
J Biol Response Mod; 1984 Dec; 3(6):634-52. PubMed ID: 6334720
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy of murine leukemia. XI. differential susceptibility of spleen cells from serum-protected mice to the in vitro immunosuppressive effects of Friend leukemia virus-infected splenocytes.
Pettey CL; Collins JJ
Int J Cancer; 1984 Aug; 34(2):269-76. PubMed ID: 6540757
[TBL] [Abstract][Full Text] [Related]
54. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
Fujihara A; Kurooka M; Miki T; Kaneda Y
Cancer Immunol Immunother; 2008 Jan; 57(1):73-84. PubMed ID: 17602226
[TBL] [Abstract][Full Text] [Related]
55. The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity.
Sinn HW; Elzey BD; Jensen RJ; Zhao X; Zhao W; Ratliff TL
Cancer Immunol Immunother; 2008 Apr; 57(4):573-9. PubMed ID: 17786441
[TBL] [Abstract][Full Text] [Related]
56. Alteration in natural defense activity against NK-susceptible B16 melanoma cells after treatment with Corynebacterium parvum.
Karashima A; Taniguchi K; Yoshikai Y; Nomoto K
Immunobiology; 1991 Aug; 182(5):414-24. PubMed ID: 1916884
[TBL] [Abstract][Full Text] [Related]
57. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
58. IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma.
Jiang Q; Wei H; Tian Z
J Immunother; 2008; 31(6):555-62. PubMed ID: 18528299
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of immunotherapy in aged leukemic mice.
Dussault I; Miller SC
Gerontology; 1995; 41(4):195-204. PubMed ID: 7557496
[TBL] [Abstract][Full Text] [Related]
60. The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections.
Tay CH; Yu LY; Kumar V; Mason L; Ortaldo JR; Welsh RM
J Immunol; 1999 Jan; 162(2):718-26. PubMed ID: 9916691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
